Ionis Pharmaceuticals

YTD

ALL

Trade Ionis Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T.

CEO

Brett P. Monia

CEOBrett P. Monia

Employees

1,402

Employees1,402

Headquarters

Carlsbad, California

HeadquartersCarlsbad, California

Founded

1989

Founded1989

Employees

1,402

Employees1,402

IONS Key Statistics

Market cap

6.54B

Market cap6.54B

Price-Earnings ratio

-11.35

Price-Earnings ratio-11.35

Dividend yield

—

Dividend yield—

Average volume

2.72M

Average volume2.72M

High today

$40.55

High today$40.55

Low today

$38.61

Low today$38.61

Open price

$39.03

Open price$39.03

Volume

2.88M

Volume2.88M

52 Week high

$86.74

52 Week high$86.74

52 Week low

$38.31

52 Week low$38.31

Stock Snapshot

As of today, Ionis Pharmaceuticals(IONS) shares are valued at $40.00. The company's market cap stands at 6.54B, with a P/E ratio of -11.35.

On 2026-11-08, Ionis Pharmaceuticals(IONS) stock moved within a range of $38.61 to $40.55. With shares now at $40.00, the stock is trading +3.6% above its intraday low and -1.4% below the session's peak.

Trading activity shows a volume of 2.88M, compared to an average daily volume of 2.72M.

The stock's 52-week range extends from a low of $38.31 to a high of $86.74.

IONS News

Simply Wall St 1d

Pelacarsen Trial Failure Might Change The Case For Investing In Ionis Pharmaceuticals Stock - Simply Wall St

...

Seeking Alpha 1d

Novartis is said to be abandoning Ionis heart drug after late-stage trial setback

Novartis (NVS) is largely abandoning the development of a heart disease therapy discovered by Ionis Pharmaceuticals (IONS) after the RNA-targeting therapy faile...

Zacks 3d

Curious about Ionis Pharmaceuticals Q3 Performance? Explore Wall Street Estimates for Key Metrics

The upcoming report from Ionis Pharmaceuticals (IONS Quick QuoteIONS - Free Report) is expected to reveal quarterly loss of -$1.00 per share, indicating...

Analyst ratings

88%

of 25 ratings

Buy

88%

Hold

12%

Sell

More IONS News

Simply Wall St 5d

Ionis Pharmaceuticals Sets A Results Webcast, Is The Stock 51% Undervalued?

Why Ionis Pharmaceuticals Is Back In Focus Ionis Pharmaceuticals (IONS) set a date for its next checkpoint. The company plans a live webcast on November 9 to r...

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.